Liquid Biopsy Market Synopsis

The Global Liquid Biopsy Market size is expected to grow from USD 1.91 billion in 2023 to USD 10.19 billion by 2032, at a CAGR of 20.42% during the forecast period (2024-2032).

A liquid biopsy is a simple and non-invasive alternative to surgical biopsies that allows doctors to learn about tumors from a simple blood sample.  In 1994, scientists advanced to the point where they could detect specific mutations in ctDNA. Dennis Lo discovered fetal cfDNA in the blood in 1997, and Veridex released the first commercially available liquid biopsy assay, the CELL SEARCH CTC test, in 2000. The FDA approved the first liquid biopsy test, the Cobas EGFR Mutation Test, as a ctDNA test for the EGFR gene mutation in lung cancer patients' blood in June 2016.

• The liquid biopsy market has witnessed significant growth and innovation, revolutionizing cancer diagnostics and monitoring. Unlike traditional tissue biopsies, liquid biopsies analyze circulating biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes in blood or other bodily fluids. This non-invasive approach offers advantages in terms of early cancer detection, treatment monitoring, and personalized medicine.
• Key drivers of the liquid biopsy market include increasing cancer prevalence, demand for minimally invasive diagnostic methods, and advancements in genomic profiling technologies. Liquid biopsies hold promise for detecting genetic mutations, assessing treatment response, and monitoring minimal residual disease.
• Key players in the liquid biopsy market include companies specializing in molecular diagnostics, genomics, and oncology. The market has witnessed collaborations and partnerships to enhance research capabilities and expand product portfolios.

Liquid Biopsy Market Trend Analysis

Increasing Prevalence of Cancer

• Cancer is still one of the leading causes of morbidity and mortality in the world. Cancer is the world's second leading cause of death, according to the WHO. According to the International Agency for Research on Cancer (IARC), the global cancer burden has risen to 19.3 million cases and 9.96 million cancer deaths in 2020.
• Liquid Biopsy is the emergence of non-invasive cancer diagnostic techniques. The results of a test are typically available much sooner than the results of a standard tissue biopsy. It is possible to make an early diagnosis using liquid biopsy, and the test can be easily repeated if necessary and used as frequently as necessary to monitor the patient's progress. The increasing prevalence of cancer supports the growth of the liquid biopsy market in the forecast period.

The Increasing Importance Of Companion Diagnostics

• Companion diagnostics are tests or assays that help healthcare providers make treatment decisions for patients based on the best response to therapy. Co-development of companion diagnostics with therapeutic products has the potential to significantly alter the drug development process and accelerate the commercialization of drug candidates by producing safer drugs with improved therapeutic efficacy quickly and cost-effectively.
• The market for companion diagnostics has a high growth potential due to the increased demand for high-priced specialist therapies and safer drugs. The increasing importance of companion diagnostics is also providing opportunities for growth in the liquid biopsy market. Thus, the future holds a lucrative opportunity for the liquid biopsy market.

Liquid Biopsy Market Segment Analysis:

Liquid Biopsy Market Segmented on the basis of Cancer type, Circulating Biomarker, and end-users.

By Cancer type, the lung cancer segment is expected to dominate the market during the forecast period

• The lung cancer segment is forecasted to dominate the liquid biopsy market in the upcoming future.  Lung cancer is the most common type of cancer diagnosed through a liquid biopsy. Liquid biopsy is a new technology that could aid in the screening and early detection of lung cancer.
• There are guidelines and expert recommendations for its use in practice, as well as specific scenarios in which liquid biopsy is actively used. Several biomarkers are currently being studied to obtain important tumor genomic information. The development of targeted therapies has resulted in higher survival rates for patients with advanced non-small-cell lung cancer (NSCLC).

By Circulating biomarkers, circulating tumor DNA segment held the largest share of xx% in 2022

• Circulating tumor DNA is expected to be the fastest-growing segment during the forecast period due to the rapid development of next-generation sequencing (NGS) technologies in liquid biopsy advancements applied to circulating tumor DNA (ctDNA).
• It is thought that the presence of circulating tumor cells (CTCs), which are found in a patient's circulation as rare abnormal cells mixed in with billions of normal red and white blood cells, is required for the development of metastatic cancer. The systems developed for the detection of CTCs have aided in the advancement of cancer treatment.

Liquid Biopsy Market Regional Insights:

Asia Pacific is Expected to Dominate the Market Over the Forecast period

• China is among the fastest-growing markets in terms of new technologies and the usage of innovative materials for construction purposes. With China's dominating role as a global construction center, the accelerated development in the 3D concrete printing sector is likely to revolutionize the traditional construction industry in the country, with applications ranging from residential buildings to monuments.
• The country is involved in the construction of buildings, offices, and bridges using 3D printing technology. Additionally, Shanghai is the home for the longest 3D-printed bridge, which is 86 feet in length in the world, consisting of 176 concrete units.

Liquid Biopsy Market Top Key Players:

• Agilent Technologies (United States)
• Bio-Rad Laboratories, Inc. (United States)
• Beckman Coulter(United States)
• Illumina (United States)
• PerkinElmer (United States)
• Becton, Dickinson and Company (BD) (United States)
• Johnson & Johnson (United States)
• Abbott Laboratories (United States)
• Cancer Genetics, Inc. (United States)
• Myriad Genetics, Inc. (United States)
• Personalis, Inc. (United States)
• Guardant Health, Inc. (United States)
• Invitae Corporation (United States)
• Exact Sciences Corporation (United States)
• Natera, Inc. (United States)
• Foundation Medicine, Inc. (United States)
• Caris Molecular Intelligence (United States)
• Blueprint Medicines Corporation (United States)
• Roche Diagnostics (Switzerland)
• Epigenomics AG (Germany)
• QIAGEN (Germany)
• AstraZeneca (United Kingdom)
• Sysmex Corporation (Japan)

Key Industry Developments in the Liquid Biopsy Market:

• In December 2023, Guardant Health announced the launch of its LUNAR-DTR test, which combines circulating tumor DNA (ctDNA) analysis with tumor mutational burden (TMB) assessment to identify patients with early-stage non-small cell lung cancer (NSCLC) at high risk of recurrence. This could potentially help personalize treatment decisions and improve patient outcomes.
• In December 2023, Epic Sciences received FDA Breakthrough Device Designation for its Colon Select test, a ctDNA-based assay for early detection of colorectal cancer (CRC). This designation highlights the potential of the test to significantly improve the way CRC is diagnosed and treated.

1. INTRODUCTION
   1. RESEARCH OBJECTIVES
   2. RESEARCH METHODOLOGY
   3. RESEARCH PROCESS
   4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
   5. MARKET SEGMENTATION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GROWTH OPPORTUNITIES BY SEGMENT
5. MARKET LANDSCAPE
   1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
   2. INDUSTRY VALUE CHAIN ANALYSIS
   3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   4. MARKET TREND ANALYSIS
   5. REGULATORY LANDSCAPE
   6. PESTLE ANALYSIS
   7. PRICE TREND ANALYSIS
   8. PATENT ANALYSIS
   9. TECHNOLOGY EVALUATION
   10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
       1. Geopolitical Market Disruptions
       2. Supply Chain Disruptions
       3. Instability in Emerging Markets
   11. ECOSYSTEM
6. LIQUID BIOPSY MARKET BY CANCER TYPE (2016-2030)
   1. LIQUID BIOPSY MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. LUNG
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. BREAST
   5. LIVER
7. LIQUID BIOPSY MARKET BY CIRULATING BIOMARKER (2016-2030)
   1. LIQUID BIOPSY MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. CIRCULATING TUMOR DNA
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. CIRCULATING TUMOR CELLS
8. LIQUID BIOPSY MARKET BY END-USER (2016-2030)
   1. LIQUID BIOPSY MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. HOSPITALS
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. LABORATORIES
   5. GOVERNMENT RESEARCH CENTRE
9. COMPANY PROFILES AND COMPETITIVE ANALYSIS
   1. COMPETITIVE LANDSCAPE
      1. Competitive Positioning
      2. LIQUID BIOPSY Market Share By Manufacturer (2022)
      3. Industry BCG Matrix
      4. Heat Map Analysis
      5. Mergers & Acquisitions
   2. AGILENT TECHNOLOGIES (UNITED STATES)
      1. Company Overview
      2. Key Executives
      3. Company Snapshot
      4. Role of the Company in the Market
      5. Sustainability and Social Responsibility
      6. Operating Business Segments
      7. Product Portfolio
      8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
      9. Key Strategic Moves And Recent Developments
      10. SWOT Analysis
   3. BIO-RAD LABORATORIES, INC. (UNITED STATES)
   4. BECKMAN COULTER (UNITED STATES)
   5. ILLUMINA (UNITED STATES)
   6. PERKINELMER (UNITED STATES)
   7. BECTON, DICKINSON AND COMPANY (BD) (UNITED STATES)
   8. JOHNSON & JOHNSON (UNITED STATES)
   9. ABBOTT LABORATORIES (UNITED STATES)
   10. CANCER GENETICS, INC. (UNITED STATES)
   11. MYRIAD GENETICS, INC. (UNITED STATES)
   12. GUARDANT HEALTH, INC. (UNITED STATES)
   13. INVITAE CORPORATION (UNITED STATES)
   14. EXACT SCIENCES CORPORATION (UNITED STATES)
   15. PERSONALIS, INC. (UNITED STATES)
   16. NATERA, INC. (UNITED STATES)
   17. FOUNDATION MEDICINE, INC. (UNITED STATES)
   18. CARIS MOLECULAR INTELLIGENCE (UNITED STATES)
   19. BLUEPRINT MEDICINES CORPORATION (UNITED STATES)
   20. ROCHE DIAGNOSTICS (SWITZERLAND)
   21. EPIGENOMICS AG (GERMANY)
   22. QIAGEN (GERMANY)
   23. ASTRAZENECA (UNITED KINGDOM)
   24. SYSMEX CORPORATION (JAPAN)
10. GLOBAL LIQUID BIOPSY MARKET BY REGION
    1. OVERVIEW
    2. NORTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Cancer Type
       4. Historic And Forecasted Market Size By Cirulating Biomarker
       5. Historic And Forecasted Market Size By End-User
       6. Historic And Forecasted Market Size By Country
          1. USA
          2. Canada
          3. Mexico
    3. EASTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Russia
          2. Bulgaria
          3. The Czech Republic
          4. Hungary
          5. Poland
          6. Romania
          7. Rest Of Eastern Europe
    4. WESTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Germany
          2. United Kingdom
          3. France
          4. The Netherlands
          5. Italy
          6. Spain
          7. Rest Of Western Europe
    5. ASIA PACIFIC
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. China
          2. India
          3. Japan
          4. South Korea
          5. Malaysia
          6. Thailand
          7. Vietnam
          8. The Philippines
          9. Australia
          10. New-Zealand
          11. Rest Of APAC
    6. MIDDLE EAST & AFRICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Turkey
          2. Bahrain
          3. Kuwait
          4. Saudi Arabia
          5. Qatar
          6. UAE
          7. Israel
          8. South Africa
    7. SOUTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Brazil
          2. Argentina
          3. Rest of South America
11. INVESTMENT ANALYSIS
12. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. LIQUID BIOPSY MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. LIQUID BIOPSY MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. LIQUID BIOPSY MARKET COMPETITIVE RIVALRY
TABLE 005. LIQUID BIOPSY MARKET THREAT OF NEW ENTRANTS
TABLE 006. LIQUID BIOPSY MARKET THREAT OF SUBSTITUTES
TABLE 007. LIQUID BIOPSY MARKET BY CANCER TYPE
TABLE 008. LUNG CANCER MARKET OVERVIEW (2016-2028)
TABLE 009. BREAST CANCER MARKET OVERVIEW (2016-2028)
TABLE 010. LIVER CANCER MARKET OVERVIEW (2016-2028)
TABLE 011. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 012. LIQUID BIOPSY MARKET BY CIRCULATING BIOMARKER
TABLE 013. CIRCULATING TUMOR DNA MARKET OVERVIEW (2016-2028)
TABLE 014. CIRCULATING TUMOR CELLS MARKET OVERVIEW (2016-2028)
TABLE 015. OTHER MARKET OVERVIEW (2016-2028)
TABLE 016. LIQUID BIOPSY MARKET BY END-USER
TABLE 017. HOSPITALS MARKET OVERVIEW (2016-2028)
TABLE 018. LABORATORIES MARKET OVERVIEW (2016-2028)
TABLE 019. GOVERNMENT RESEARCH CENTERS MARKET OVERVIEW (2016-2028)
TABLE 020. NORTH AMERICA LIQUID BIOPSY MARKET, BY CANCER TYPE (2016-2028)
TABLE 021. NORTH AMERICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER (2016-2028)
TABLE 022. NORTH AMERICA LIQUID BIOPSY MARKET, BY END-USER (2016-2028)
TABLE 023. N LIQUID BIOPSY MARKET, BY COUNTRY (2016-2028)
TABLE 024. EUROPE LIQUID BIOPSY MARKET, BY CANCER TYPE (2016-2028)
TABLE 025. EUROPE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER (2016-2028)
TABLE 026. EUROPE LIQUID BIOPSY MARKET, BY END-USER (2016-2028)
TABLE 027. LIQUID BIOPSY MARKET, BY COUNTRY (2016-2028)
TABLE 028. ASIA PACIFIC LIQUID BIOPSY MARKET, BY CANCER TYPE (2016-2028)
TABLE 029. ASIA PACIFIC LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER (2016-2028)
TABLE 030. ASIA PACIFIC LIQUID BIOPSY MARKET, BY END-USER (2016-2028)
TABLE 031. LIQUID BIOPSY MARKET, BY COUNTRY (2016-2028)
TABLE 032. MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, BY CANCER TYPE (2016-2028)
TABLE 033. MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER (2016-2028)
TABLE 034. MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, BY END-USER (2016-2028)
TABLE 035. LIQUID BIOPSY MARKET, BY COUNTRY (2016-2028)
TABLE 036. SOUTH AMERICA LIQUID BIOPSY MARKET, BY CANCER TYPE (2016-2028)
TABLE 037. SOUTH AMERICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER (2016-2028)
TABLE 038. SOUTH AMERICA LIQUID BIOPSY MARKET, BY END-USER (2016-2028)
TABLE 039. LIQUID BIOPSY MARKET, BY COUNTRY (2016-2028)
TABLE 040. F. HOFFMANN-LA ROCHE LTD.: SNAPSHOT
TABLE 041. F. HOFFMANN-LA ROCHE LTD.: BUSINESS PERFORMANCE
TABLE 042. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 043. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. MYRIAD GENETICS INC.: SNAPSHOT
TABLE 044. MYRIAD GENETICS INC.: BUSINESS PERFORMANCE
TABLE 045. MYRIAD GENETICS INC.: PRODUCT PORTFOLIO
TABLE 046. MYRIAD GENETICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. QIAGEN N.V.: SNAPSHOT
TABLE 047. QIAGEN N.V.: BUSINESS PERFORMANCE
TABLE 048. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 049. QIAGEN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. THERMO FISHER SCIENTIFIC INC.: SNAPSHOT
TABLE 050. THERMO FISHER SCIENTIFIC INC.: BUSINESS PERFORMANCE
TABLE 051. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 052. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. GUARDANT HEALTH INC.: SNAPSHOT
TABLE 053. GUARDANT HEALTH INC.: BUSINESS PERFORMANCE
TABLE 054. GUARDANT HEALTH INC.: PRODUCT PORTFOLIO
TABLE 055. GUARDANT HEALTH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. BIOCEPT INC.: SNAPSHOT
TABLE 056. BIOCEPT INC.: BUSINESS PERFORMANCE
TABLE 057. BIOCEPT INC.: PRODUCT PORTFOLIO
TABLE 058. BIOCEPT INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. ILLUMINA INC.: SNAPSHOT
TABLE 059. ILLUMINA INC.: BUSINESS PERFORMANCE
TABLE 060. ILLUMINA INC.: PRODUCT PORTFOLIO
TABLE 061. ILLUMINA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. ANGLE PLC.: SNAPSHOT
TABLE 062. ANGLE PLC.: BUSINESS PERFORMANCE
TABLE 063. ANGLE PLC.: PRODUCT PORTFOLIO
TABLE 064. ANGLE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. ONCIMMUNE: SNAPSHOT
TABLE 065. ONCIMMUNE: BUSINESS PERFORMANCE
TABLE 066. ONCIMMUNE: PRODUCT PORTFOLIO
TABLE 067. ONCIMMUNE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. LUCENCE HEALTH INC.: SNAPSHOT
TABLE 068. LUCENCE HEALTH INC.: BUSINESS PERFORMANCE
TABLE 069. LUCENCE HEALTH INC.: PRODUCT PORTFOLIO
TABLE 070. LUCENCE HEALTH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. FREENOMEHOLDINGS INC.: SNAPSHOT
TABLE 071. FREENOMEHOLDINGS INC.: BUSINESS PERFORMANCE
TABLE 072. FREENOMEHOLDINGS INC.: PRODUCT PORTFOLIO
TABLE 073. FREENOMEHOLDINGS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 074. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 075. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 076. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. LIQUID BIOPSY MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. LIQUID BIOPSY MARKET OVERVIEW BY CANCER TYPE
FIGURE 012. LUNG CANCER MARKET OVERVIEW (2016-2028)
FIGURE 013. BREAST CANCER MARKET OVERVIEW (2016-2028)
FIGURE 014. LIVER CANCER MARKET OVERVIEW (2016-2028)
FIGURE 015. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 016. LIQUID BIOPSY MARKET OVERVIEW BY CIRCULATING BIOMARKER
FIGURE 017. CIRCULATING TUMOR DNA MARKET OVERVIEW (2016-2028)
FIGURE 018. CIRCULATING TUMOR CELLS MARKET OVERVIEW (2016-2028)
FIGURE 019. OTHER MARKET OVERVIEW (2016-2028)
FIGURE 020. LIQUID BIOPSY MARKET OVERVIEW BY END-USER
FIGURE 021. HOSPITALS MARKET OVERVIEW (2016-2028)
FIGURE 022. LABORATORIES MARKET OVERVIEW (2016-2028)
FIGURE 023. GOVERNMENT RESEARCH CENTERS MARKET OVERVIEW (2016-2028)
FIGURE 024. NORTH AMERICA LIQUID BIOPSY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. EUROPE LIQUID BIOPSY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. ASIA PACIFIC LIQUID BIOPSY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. SOUTH AMERICA LIQUID BIOPSY MARKET OVERVIEW BY COUNTRY (2016-2028)